Key Potential Benefits of Cagrilintide + Semaglutide (CagriSema)

1. Superior Weight Loss (Potentially Among the Strongest Non-Surgical Options)

   • In REDEFINE 1 (adults with overweight/obesity without diabetes): Mean body weight reduction of 20.4% (treatment policy) to 22.7% (if all adhered to treatment) at 68 weeks, with continued loss and no clear plateau in many participants; 40–53% achieved ≥20% weight loss and up to 34.7% achieved ≥25%.

   • In REDEFINE 2 (adults with overweight/obesity and type 2 diabetes): Mean weight loss of 13.7–15.7% at 68 weeks.

   • In REIMAGINE 2 (type 2 diabetes): 14.2% weight loss vs 10.2% with semaglutide 2.4 mg alone at 68 weeks.

   • Outperforms monotherapy: Superior to semaglutide alone (by ~5.5%) and cagrilintide alone (by ~8.9%) in head-to-head comparisons, approaching or rivaling outcomes seen with more invasive interventions in select data.

2. Enhanced Satiety, Appetite Control, and Reduced Food Intake

   • Cagrilintide activates amylin receptors in the brainstem and hypothalamus to promote profound feelings of fullness, reduce hunger signals, and blunt the rewarding aspects of food.

   • Semaglutide provides strong GLP-1-mediated appetite suppression, delayed gastric emptying, and reduced cravings.

   • Together: Complementary multi-pathway reinforcement (GLP-1 + amylin) leads to more robust and sustained satiety, improved adherence, and fewer compensatory hunger episodes compared to either agent alone.

3. Improved Glycemic Control and Type 2 Diabetes Management

   • Significant HbA1c reductions: Up to 1.91 percentage points in REIMAGINE 2 (superior to 1.76 points with semaglutide alone); ~1.8–2.2 points in earlier trials.

   • High rates of target achievement: 73.5% reaching HbA1c ≤6.5% and up to 89% reaching <7.0% in some studies.

   • Enhances insulin sensitivity, suppresses postprandial glucagon, and supports better overall glucose regulation, with potential for prediabetes reversal or normoglycemia in a large proportion of participants.

4. Favorable Cardiometabolic and Body Composition Improvements

   • Reductions in waist circumference (up to –13.4 cm), systolic blood pressure (–6.7 to –10.9 mmHg), and inflammatory markers (e.g., high-sensitivity C-reactive protein).

   • Improvements in lipid profiles, liver fat, and other metabolic parameters beyond what weight loss alone explains in some analyses.

   • Supports better physical function scores (e.g., IWQOL-Lite-CT and SF-36) and overall quality of life related to mobility and daily activities.

5. Synergistic Advantages Over Monotherapy

   • Dual targeting of complementary hunger/satiety pathways (GLP-1 for central and gut effects + amylin for brainstem reinforcement) creates broader appetite regulation and potentially delays or reduces weight loss plateaus.

   • Additive effects on energy balance, gastric motility, and metabolic signaling lead to greater total weight reduction and metabolic benefits than semaglutide or cagrilintide used individually.

   • Maintains a profile consistent with the GLP-1 class while delivering meaningful incremental efficacy through amylin co-activation.